Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to ...

Vertical farms, woke AI, and 23andMe made our annual list of failed tech. A two-hour interview is enough to accurately capture your values and preferences, according to new research from Stanford ...

Vertical farms, woke AI, and 23andMe made our annual list of failed tech. A two-hour interview is enough to accurately capture your values and preferences, according to new research from Stanford and ...

For more on other class-action settlements, find out if you're eligible for 23andMe's data breach settlement ... For more, see why Apple claims that AI will enhance its privacy offerings while ...

23andMe has been steadily expanding beyond its ... Reimagining What's Possibl Artificial intelligence (AI) has long promised to transform the life sciences, but today, we stand at a critical ...

A complete list of all the known layoffs in tech, from Big Tech to startups, broken down by month throughout 2024. © 2024 TechCrunch. All rights reserved. For personal use only.

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

The struggling health company bought virtual care startup Lemonaid in 2021 for $400 million. 23andMe's stock has plummeted after a 2023 data breach exposed millions of customer accounts.

23andMe CEO Anne Wojcicki sounded optimistic about the company's future during an earnings call in February last year. She said the biotech company, which offers direct-to-consumer genetic testing ...

23andMe faced major hurdles in 2024, including a $30 million settlement related to compromised data. 23andMe is now restructuring its business operations to reduce costs and streamline operations ...